510 related articles for article (PubMed ID: 22280340)
1. Cannabinoids: novel medicines for the treatment of Huntington's disease.
Sagredo O; Pazos MR; Valdeolivas S; Fernandez-Ruiz J
Recent Pat CNS Drug Discov; 2012 Apr; 7(1):41-8. PubMed ID: 22280340
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
Sagredo O; Pazos MR; Satta V; Ramos JA; Pertwee RG; Fernández-Ruiz J
J Neurosci Res; 2011 Sep; 89(9):1509-18. PubMed ID: 21674569
[TBL] [Abstract][Full Text] [Related]
3. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097
[TBL] [Abstract][Full Text] [Related]
4. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
[TBL] [Abstract][Full Text] [Related]
5. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
6. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids and neuroprotection in motor-related disorders.
de Lago E; Fernández-Ruiz J
CNS Neurol Disord Drug Targets; 2007 Dec; 6(6):377-87. PubMed ID: 18220777
[TBL] [Abstract][Full Text] [Related]
8. Medical Use of Cannabinoids.
Fraguas-Sánchez AI; Torres-Suárez AI
Drugs; 2018 Nov; 78(16):1665-1703. PubMed ID: 30374797
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids for Treatment of Dystonia in Huntington's Disease.
Saft C; von Hein SM; Lücke T; Thiels C; Peball M; Djamshidian A; Heim B; Seppi K
J Huntingtons Dis; 2018; 7(2):167-173. PubMed ID: 29562549
[TBL] [Abstract][Full Text] [Related]
10. [Marihuana and cannobinoids as medicaments].
Tkaczyk M; Florek E; Piekoszewski W
Przegl Lek; 2012; 69(10):1095-7. PubMed ID: 23421098
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids in the management of difficult to treat pain.
Russo EB
Ther Clin Risk Manag; 2008 Feb; 4(1):245-59. PubMed ID: 18728714
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
López-Sendón Moreno JL; García Caldentey J; Trigo Cubillo P; Ruiz Romero C; García Ribas G; Alonso Arias MA; García de Yébenes MJ; Tolón RM; Galve-Roperh I; Sagredo O; Valdeolivas S; Resel E; Ortega-Gutierrez S; García-Bermejo ML; Fernández Ruiz J; Guzmán M; García de Yébenes Prous J
J Neurol; 2016 Jul; 263(7):1390-400. PubMed ID: 27159993
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders.
Antonazzo M; Botta M; Bengoetxea H; Ruiz-Ortega JÁ; Morera-Herreras T
Int Rev Neurobiol; 2019; 146():229-257. PubMed ID: 31349929
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases.
Pérez-Olives C; Rivas-Santisteban R; Lillo J; Navarro G; Franco R
Adv Exp Med Biol; 2021; 1264():81-92. PubMed ID: 33332005
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of cannabinoids for movement disorders.
Kluger B; Triolo P; Jones W; Jankovic J
Mov Disord; 2015 Mar; 30(3):313-27. PubMed ID: 25649017
[TBL] [Abstract][Full Text] [Related]
16. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
17. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Barnes MP
Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids, inflammation, and fibrosis.
Zurier RB; Burstein SH
FASEB J; 2016 Nov; 30(11):3682-3689. PubMed ID: 27435265
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of cannabinoids in CNS disease.
Croxford JL
CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
